EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells

Cellular & Molecular Biology Letters

Research

Xuli Jin¹  Xin Shen²  Jie Chen²  Shuang Fang³ 

[1] Department of Epidemiology, School of Public Health, Cheeloo College of Medicine, Shandong University, 250012, Jinan, Shandong, China;Department of Maternal and Child Health, School of Public Health, Cheeloo College of Medicine, Shandong University, 250012, Jinan, Shandong, China;Jinan Medical Center Management Committee, 250000, Jinan, China;

关键词: Ovarian cancer;    EFEMP2;    PD-L1;    EGFR;    ERK1/2/c-Jun pathway;    Trametinib;    Afatinib;   

DOI  :  10.1186/s11658-023-00471-8

 received in 2023-02-19, accepted in 2023-06-24,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundFibulin-like extracellular matrix protein 2 (EFEMP2) has been reported to be related to the progression of various cancers. We have previously reported that EFEMP2 was highly expressed in ovarian cancer and was strongly associated with poor prognosis in patients. This study intends to further explore its interacting proteins and possible downstream signaling pathways.MethodThe expression of EFEMP2 was detected by RT-qPCR, ICC and western blot in 4 kinds of ovarian cancer cells with different migration and invasion ability. Cell models with strong or weak EFEMP2 expression were constructed by lentivirus transfection. The effects of the down-regulation and up-regulation of EFEMP2 on the biological behavior of ovarian cancer cells were studied through in-vitro and in-vivo functional tests. The phosphorylation pathway profiling array and KEGG database analyses identified the downstream EGFR/ERK1/2/c-Jun signaling pathway and the programmed death-1 (PD-L1) pathway enrichment. Additionally, the protein interaction between EFEMP2 and EGFR was detected by immunoprecipitation.ResultEFEMP2 was positively correlated with the invasion ability of ovarian cancer cells, its down-regulation inhibited the migrative, invasive and cloning capacity of cancer cells in vitro and suppressed the tumor proliferation and intraperitoneal diffusion in vivo, while its up-regulation did the opposite. Moreover, EFEMP2 could bind to EGFR to induce PD-L1 regulation in ovarian cancer, which was caused by the activation of EGFR/ERK1/2/c-Jun signaling. Similar to EFEMP2, PD-L1 was also highly expressed in aggressive cells and had the ability to promote the invasion and metastasis of ovarian cancer cells both in vitro and in vivo, and PD-L1 upregulation was partly caused by EFEMP2 activation. Afatinib combined with trametinib had an obvious effect of inhibiting the intraperitoneal diffusion of ovarian cancer cells, especially in the group with low expression of EFEMP2, while overexpression of PD-L1 could reverse this phenomenon.ConclusionEFEMP2 could bind to EGFR to activate ERK1/2/c-Jun pathway and regulate PD-L1 expression, furthermore PD-L1 was extremely essential for EFEMP2 to promote ovarian cancer cells invasion and dissemination in vitro and in vivo. Targeted therapy against the source gene EFEMP2 is our future research direction, which may better inhibit the invasion and metastasis of ovarian cancer cells.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 8

Fig. 3

Fig. 3

40708_2023_197_Article_IEq86.gif

Fig. 2

40708_2023_197_Article_IEq50.gif

Fig. 2

Fig. 1